Allogeneic CD19-targeted CAR-T Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia
Status:
RECRUITING
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This clinical trial aims to investigate the safety, optimal dosage, and effectiveness of allogeneic CD19-targeted CAR-T Cell in treating CD19-positive relapsed/refractory B-ALL
Phase:
EARLY_PHASE1
Details
Lead Sponsor:
The First Affiliated Hospital of Soochow University